nVerses Capital’s Spyre Therapeutics SYRE Stock Holding History

nVerses Capital’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$14.7K	–	795
2024 Q3	$14.7K	Buy	+500	New	+$13.9K	0.01%	845

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

nVerses Capital's SYRE Position: Q4 2024 in Review

nVerses Capital sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 500 shares — an estimated $14.7K sold.

nVerses Capital first reported a position in SYRE in Q3 2024 and held it in 1 quarter. The position peaked at $14.7K in Q3 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

nVerses Capital reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 500 Spyre Therapeutics shares in Q4 2024, an estimated $14.7K.
nVerses Capital first reported a position in Spyre Therapeutics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Spyre Therapeutics position peaked at $14.7K in Q3 2024.
131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.